02 February 2018
London
Reporter: Barney Dixon

Changes to generic drug processes should be “carefully assessed”


Changes to generic and biosimilar drug approval processes should be “carefully assessed” to ensure that the development of new drugs is not undermined, according to Kevin O’Connor, partner at Neal Gerber & Eisenberg.

Kevin explains that “as the pharmaceutical landscape shifts from blockbuster drugs to more targeted therapeutics and precision medicine, it will remain as important as ever to balance the incentives for investment in innovative therapies with the desire to ensure competition after a reasonable period of exclusivity for the innovator product.”

At a recent US Federal Trade Commission workshop, US Food and Drug Administration commissioner Scott Gottlieb identified certain practices that delay generic entry may face increased governmental scrutiny.

The workshop focused on competition in the drug market and on strategies to encourage competition in order to lower prices and improve access.

According to Kevin, the workshop saw general agreement that it “continues to be important to protect intellectual property rights associated with new pharmaceuticals so that innovative companies have appropriate economic incentives to develop vital new drugs and undertake the costly work necessary to demonstrate safety and efficacy”.

But Kevin says that potential governmental scrutiny could harm incentives for pharmaceutical companies and potentially have a knock-on effect for innovation and should be carefully assessed before being implemented.

Subscribe for free to read the next issue of IPPro Patents, published on 7 February, to read this article in full.

More news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
Countries should break IP rules to ensure growth, says report
23 February 2018 | London | Reporter: Barney Dixon
Countries such as India and China should break harmonised intellectual property rules to avoid protectionist measures from the US and EU, according to a new report from Gowling WLG
EPO employment proposal halted
22 February 2018 | Munich | Reporter: Barney Dixon
A proposal to scrap permanent employment contracts at the EPO has been halted and a controversial article within it withdrawn, a source close to the Staff Union of the EPO has confirmed
UPC complaint to be heard in 2018
22 February 2018 | Karlsruhe | Reporter: Barney Dixon
The German Federal Constitutional Court will hear the constitutional complaint against the UPC in 2018
Cabinet Plasseraud promotes four to partner
21 February 2018 | Paris | Reporter: Barney Dixon
Cabinet Plasseraud has appointed for intellectual property attorneys to partner
NPE litigation in Europe sees continued growth
20 February 2018 | Brussels | Reporter: Barney Dixon
NPE litigation and enforcement in Europe has increased by an average almost 20 percent year-on-year since 2007, according to a new report from Darts-IP
BakerHostetler hires IP partner
19 February 2018 | Los Angeles | Reporter: Barney Dixon
BakerHostetler has hired Troy Schmelzer as partner in its intellectual property group
Sheppard, Mullin, Richter & Hampton promotes four to partner
16 February 2018 | California | Reporter: Barney Dixon
Sheppard, Mullin, Richter & Hampton has promoted four intellectual property attorneys to partner across its Shanghai, San Diego and San Francisco offices